A Phase 3 interventional study of FDC tiotropium / salmeterol and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim. Terminated at 72 sites in 18 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Boehringer Ingelheim.
Among the 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim, this one is the 66th largest by enrollment of the 155 interventional ones that give a count, is one of 11 that started in 2008, is one of 81 in phase 3, and was the 59th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim is open now, in 3 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Italy, Malaysia
Ages 40+
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 11 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 166 across the 155 interventional studies, 1,577 across the 80 observational. Of the 232 that completed or were terminated, 124 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 61 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea Index (BDI/TDI), the effect on health status as determined by the St George Respiratory Questionnaire (SGRQ) and the effect on chronic obstructive pulmonary disease (COPD) exacerbations.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Main:
Exclusion criteria:
Main:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One fixed dose combination (FDC) capsule of inhalation powder containing 7.5 micrograms Tiotropium and 25 micrograms of salmeterol were administered orally once daily in the morning from blue HandiHaler® device for treatment duration of 24 weeks (+24 week extension). One capsule of inhalation powder of placebo was administered twice daily in the morning from the grey HandiHaler® device, and in the evening from blue HandiHaler® device. The morning and evening dose of study medication had to be taken at approximately the same time, the evening dose had to be taken approximately 12 hours after the morning dose. All medications were self-administered by patients.
Drug: FDC tiotropium / salmeterol
One dose gelatine capsule of inhalation powder containing 18 micrograms tiotropium was administered orally once daily in the morning from the grey HandiHaler® device for treatment duration of 24 weeks (+24 week extension). One capsule of inhalation powder of placebo was administered twice daily in the morning and evening from the blue HandiHaler® device. The morning and evening dose of study medication had to be taken at approximately the same time, the evening dose had to be taken approximately 12 hours after the morning dose. All medications were self-administered by patients.
Drug: Tiotropium (Spiriva®)
One dose polyethylene capsule of inhalation powder containing 25 micrograms salmeterol was administered orally twice daily in the morning and evening from the blue HandiHaler® device for treatment duration of 24 weeks (+24 week extension). One capsule of inhalation powder of placebo was administered once daily in the morning from the grey HandiHaler® device. The morning and evening dose of study medication had to be taken at approximately the same time, the evening dose had to be taken approximately 12 hours after the morning dose. All medications were self-administered by patients.
Drug: Salmeterol
One fixed dose combination (FDC) capsule of inhalation powder containing 7.5 micrograms tiotropium and 25 micrograms salmeterol was administered orally once daily in the morning from the blue HandiHaler® device and one dose of inhalation powder containing 25 micrograms salmeterol was administered once daily in the evening from the blue HandiHaler® device for treatment duration of 24 weeks (+24 week extension). One capsule of inhalation powder of placebo was administered once daily in the morning from the grey HandiHaler® device. The morning and evening dose of study medication had to be taken at approximately the same time, the evening dose had to be taken approximately 12 hours after the morning dose. All medications were self-administered by patients.
Drug: FDC tiotropium / salmeterol · Drug: Salmeterol
One capsule of inhalation powder of placebo was administered daily in the morning from the blue and grey HandiHaler® device and in the evening from the blue HandiHaler® device for treatment duration of 12 weeks (Patients randomized into the placebo group will be re-assigned at random to one of the four active treatments (T+S\_PE, Tio18GEL, Salm25PE, T+S\_PE/S25PE) for the remaining 36 weeks of the 48-week study period.). The morning and evening dose of study medication had to be taken at approximately the same time, the evening dose had to be taken approximately 12 hours after the morning dose. All medications were self-administered by patients.
Drug: Placebo
Fixed-dose combination Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene (PE) Capsule
Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
Salmeterol Inhalation Powder, hard PE capsule
Tiotropium, Spiriva®
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period
Change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the end of the 12-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FEV1 response is defined as the change from baseline: Trough FEV1 response = Trough FEV1 - FEV1 (Baseline)
Time frame: At baseline and week 12
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period
Change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the end of the 24-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 min time point just prior to inhalation of the morning dose of randomised treatment.
Time frame: At baseline and week 24
Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 12-week Treatment Period
Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response at the end of the 12-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 12 - trough FEV1 at baseline.
Time frame: At baseline and at week 12: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 24-week Treatment Period
Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response at the end of the 24-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 24 - trough FEV1 at baseline.
Time frame: At baseline and at week 24: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Mahler Transition Dyspnoea Index (TDI) Focal Score at the End of the 12-week Treatment Period
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major deterioration) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.
Time frame: At the end of week 12
Mahler Transition Dyspnoea Index (TDI) Focal Score at the End of the 24-week Treatment Period
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major deterioration) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.
Time frame: At the end of week 24
St George Respiratory Questionnaire (SGRQ) Total Score at the End of the 24-week Treatment Period (Based Upon Pooled Data From 48-week Sister Studies 1184.14 and 1184.15)
The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations. The evaluation SGRQ was planned to be based upon pooled data from 48-week sister studies 1184.14 and 1184.15.
Time frame: At the end of week 24
Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Within 48 Weeks
Time from start of treatment to first moderate to severe chronic obstructive pulmonary disease (COPD) exacerbation within 48 weeks is presented.
Time frame: Up to 12 weeks
Number of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Within 48 Weeks
Number of patients with moderate to severe chronic obstructive pulmonary disease (COPD) exacerbations within 48 weeks is presented.
Time frame: Up to 12 weeks.
Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 36 and 48 Weeks Treatment Period
Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response after 4, 36 and 48 weeks treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 4, 36 or 48 - trough FEV1 at baseline.
Time frame: At baseline and at week 4: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) After 4, 36 and 48 Weeks Treatment Period
Change from baseline in trough Forced Expiratory Volume in one second (FEV1) after 4, 36 and 48 weeks treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FEV1 response is defined as the change from baseline: Trough FEV1 response = Trough FEV1 - FEV1 (Baseline)
Time frame: At baseline and week 4
Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1) at Week 4, 12, 18, 24, 36 and 48
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Peak FEV1 is defined as the highest FEV1 reading observed within 3 hours after inhalation of the morning dose of randomised treatment. Peak FEV1 response is defined as the change from baseline: Peak FEV1 response = Peak FEV1 - FEV1 (Baseline)
Time frame: At baseline and at week 4 and 12: within 3h after inhalation of the morning dose of randomised treatment.
The Forced Vital Capacity (FVC) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 12, 24, 36 and 48 Weeks Treatment Period
Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC AUC0-8h is defined as the area under the FVC curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FVC was assigned to zero time. Trough FVC at baseline is defined as the pre-dose FVC measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FVC AUC0-8h at week 4, 12, 24, 36 or 48 - trough FVC at baseline.
Time frame: At baseline and at week 4 and 12: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Change From Baseline in Trough Forced Vital Capacity (FVC) After 4, 12, 24, 36 and 48 Weeks Treatment Period
Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC is defined as the pre-dose FVC measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FVC response is defined as the change from baseline: Trough FVC response = Trough FVC - FVC (Baseline)
Time frame: At baseline and week 4 and 12
Change From Baseline in Peak Forced Vital Capacity (FVC) at Week 4, 12, 18, 24, 36 and 48
Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Peak FVC is defined as the highest FVC reading observed within 3 hours after inhalation of the morning dose of randomised treatment. Peak FVC response is defined as the change from baseline: Peak FVC response = Peak FVC - FVC (Baseline)
Time frame: At baseline and at week 4 and 12: within 3 hours after inhalation of the morning dose of randomised treatment.
Forced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 4
Forced Expiratory Volume in one second (FEV1) at clinic visits at the individual times on week 4 is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer.
Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Forced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 12
Forced Expiratory Volume in one second (FEV1) at clinic visits at the individual times on week 12 is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer.
Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Forced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 4
Forced Vital Capacity (FVC) at clinic visits at the individual times on week 4 is presented. Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible.
Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Forced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 12
Forced Vital Capacity (FVC) at clinic visits at the individual times on week 12 is presented. Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible.
Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Peak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 4
Peak expiratory flow (PEF) rate at clinic visits at the individual times on week 4 is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.
Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Peak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 12
Peak expiratory flow (PEF) rate at clinic visits at the individual times on week 12 is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.
Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Weekly Mean Morning Pre-dose Peak Expiratory Flows (PEFs)
Weekly mean morning pre-dose peak expiratory flows (PEFs) is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. The pulmonary function test was obtained by spirometry. The best of three efforts was defined as the highest PEF. Patients did not take their morning study medications prior to each morning PEF measurement.
Time frame: At week 1 to 14, each morning between 7 a.m. and 10 a.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
Weekly Mean Evening Pre-dose Peak Expiratory Flows (PEFs)
Weekly mean evening pre-dose peak expiratory flows (PEFs) is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. The pulmonary function test was obtained by spirometry. The best of three efforts was defined as the highest PEF. Patients did not take their evening study medications prior to each evening PEF measurement.
Time frame: At week 1 to 14, each evening between 7 p.m. and 10 p.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
Peak Expiratory Flow (PEF) Determined by Spirometry at Week 4, 12, 18, 24, 36 and 48
Peak expiratory flow (PEF) are determined by spirometry at clinic visits (week 4, 12, 18, 24, 36 and 48) is presented. Spirometry will begin between 07:00 and 10:00 a.m. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.
Time frame: At week 4 and 12: 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment.
Weekly Mean Morning Pre-dose Forced Expiratory Volume in One Second (FEV1)
Weekly mean morning pre-dose Forced expiratory volume in one second (FEV1) is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 measurements are performed individually at home and reported by the patient. It is measured by a spirometer. The best of three efforts was defined as the highest FEV1. Patients did not take their morning study medications prior to each morning FEV1 measurement.
Time frame: At week 1 to 14, each morning between 7 a.m. and 10 a.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
Weekly Mean Evening Pre-dose Forced Expiratory Volume in One Second (FEV1)
Weekly mean evening pre-dose Forced expiratory volume in one second (FEV1) is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 measurements are performed individually at home and reported by the patient. It is measured by a spirometer. The best of three efforts was defined as the highest FEV1. Patients did not take their evening study medications prior to each evening FEV1 measurement.
Time frame: At week 1 to 14, each morning between 7 p.m. and 10 p.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
Weekly Mean Number Per Day of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)
Weekly mean number per day of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).
Time frame: Weekly up to week 14: per day (24 hours period)
Weekly Mean Number at Daytime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)
Weekly mean number at daytime of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).
Time frame: Weekly up to week 14: at daytime (from morning dose till evening dose of study medication)
Weekly Mean Number at Nighttime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)
Weekly mean number at nighttime of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).
Time frame: Weekly up to week 14: at nighttime (from evening dose till morning dose of study medication)
Weekly Mean Number of Chronic Obstructive Pulmonary Disease (COPD)-Related Nighttime Awakenings
Weekly mean number of chronic obstructive pulmonary disease (COPD)-related nighttime awakenings is presented.
Time frame: Per week, up to 14 weeks
Mahler Transition Dyspnoea Index (TDI) Focal Score Collected After 4, 36 and 48 Weeks Treatment Period
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major detonation) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.
Time frame: At week 4
Mahler Transition Dyspnoea Index (TDI) Domain Score - Functional Impairment Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - functional impairment is based on the criteria of change in functional impairment (any activities started or stopped?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).
Time frame: At the end of week 4 and 12.
Mahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Task Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - magnitude of task is based on the criteria of change in magnitude of task (What activities cause breathlessness now?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).
Time frame: At the end of week 4 and 12.
Mahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Effort Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - magnitude of effort is based on the criteria of change in magnitude of effort (Need to pause while performing activities?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).
Time frame: At the end of week 4 and 12.
St George Respiratory Questionnaire (SGRQ) Total Score Collected at 4, 12, 36 and 48 Weeks
The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: At week 4 and 12.
St George Respiratory Questionnaire (SGRQ) Impact Domain Score Collected at 4, 12, 36 and 48 Weeks
The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The impact domain score is a part of the SGRQ that measures the impact of disease on daily life. Its scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: At week 4 and 12.
St George Respiratory Questionnaire (SGRQ) Activity Domain Score Collected at 4, 12, 36 and 48 Weeks
The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The activity domain score is a part of the SGRQ that measures the activity of the patient. Its scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: At week 4 and 12.
St George Respiratory Questionnaire (SGRQ) Symptoms Domain Score Collected at 4, 12, 36 and 48 Weeks
The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The symptoms domain score is a part of the SGRQ that measures the symptoms of the patient. Its scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: At week 4 and 12.
Number of Patients With Adverse Events Within the 48-week Treatment Period
Number of patients with adverse events within the 48-week treatment period is presented. A patient may be counted in more than one seriousness criterion.
Time frame: From randomisation till end of treatment, up to 12 weeks.
Number of Patients With Marked Changes in Vital Signs (Decrease) by Clinic Visit
Number of patients with marked changes in vital signs (decrease) by clinic visit is presented. Vital signs: pulse rate and blood pressure (BP) (after five minutes rest in seated position) recorded pre-dose on each pulmonary function test-day and in conjunction with spirometry for the first 3 hours post-dosing. Systolic BP Decrease: Below 100 mmHg if not at that level at baseline and a decrease of greater than 10 mmHg below baseline. Diastolic BP Decrease: Below 60 mmHg if not at that level at baseline and a decrease of greater than 10 mmHg below baseline. Pulse rate Decrease: Below 60 bpm if not at that level at baseline and a decrease of greater than 10 bpm below baseline.
Time frame: At baseline, week 4 and week 12.
Number of Patients With Marked Changes in Vital Signs (Increase) by Clinic Visit
Number of patients with marked changes in vital signs (increase) by clinic visit is presented. Vital signs: pulse rate and blood pressure 8BP) (after five minutes rest in seated position) recorded pre-dose on each pulmonary function test-day and in conjunction with spirometry for the first 3 hours post-dosing. Systolic BP Increase : An increase of 25 mmHg or more above baseline. Diastolic BP Increase: Above 90 mmHg at baseline and an increase of greater than 10 mmHg above baseline. Pulse rate Increase : Greater than 100 bpm if not at that level at baseline and an increase greater than 10 above baseline.
Time frame: At baseline, week 4 and week 12.
Number of Patients With Abnormal Haematology at the End of the 12-week Treatment Period
Number of patients with abnormal haematology at the end of the 12-week treatment period is presented.
Time frame: At the end of the 12-week treatment period.
Number of Patients With Abnormal Blood Chemistry at the End of the 12-week Treatment Period
Number of patients with abnormal blood chemistry at the end of the 12-week treatment period is presented.
Time frame: At the end of the 12-week treatment period.
Number of Patients With Abnormal Urinalysis at the End of the 12-week Treatment Period
Number of patients with abnormal urinalysis at the end of the 12-week treatment period is presented.
Time frame: At the end of the 12-week treatment period.
Vital Status of Randomised Patients
Vital status of randomised patients is presented.
Time frame: Up to 48 weeks.
Number of Days in Hospital Within the 48-week Treatment Period
Number of days in hospital within the 48-week treatment period is presented.
Time frame: Up to 12 weeks.
Number of Unscheduled Health Care Provider Visits Within the 48-week Treatment Period
Number of unscheduled health care provider visits within the 48-week treatment period is presented.
Time frame: Up to 12 weeks.
Number of Emergency Room Visits Within the 48-week Treatment Period
Number of emergency room visits within the 48-week treatment period is presented.
Time frame: Up to 12 weeks.
Number of Days in Intensive Care Unit Within the 48-week Treatment Period
Number of days in intensive care unit within the 48-week treatment period is presented.
Time frame: Up to 12 weeks.
Number of Patients Receiving Concomitant Medication
Number of patients receiving concomitant medication is presented. Concomitant medication was observed for rerandomized placebo patients during placebo treatment and on-treatment periods.
Time frame: Up to 12 weeks.
24-week (+ 24 week extension) placebo-controlled (only 1st 12-week period), double-blind, parallel-group, efficacy and safety study in chronic obstructive pulmonary disease (COPD) patients. Participants randomised to the placebo arm will be randomly re-assigned to one of the four active treatments after completing the 12-week period.
| Milestone | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Started | 41 | 42 | 49 | 44 | 44 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 41 | 42 | 49 | 44 | 44 |
| Withdrew: Trial termination for strategic reasons | 41 | 40 | 44 | 42 | 38 |
| Withdrew: Adverse event | 0 | 0 | 2 | 1 | 2 |
| Withdrew: Refused to continue taking the drug | 0 | 0 | 2 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 | 0 | 2 |
Change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the end of the 12-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FEV1 response is defined as the change from baseline: Trough FEV1 response = Trough FEV1 - FEV1 (Baseline)
| Litres (L) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period | 1.530 ± 0.598 | 0.990 ± 0.283 | — | 1.905 ± 0.520 | 0.640 ± 0.537 |
Change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the end of the 24-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 min time point just prior to inhalation of the morning dose of randomised treatment.
No measurements were reported for this outcome.
Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response at the end of the 12-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 12 - trough FEV1 at baseline.
| Litres (L) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 12-week Treatment Period | 1.659 ± 0.633 | 1.048 ± 0.338 | — | 1.948 ± 0.521 | 0.802 ± 0.545 |
Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response at the end of the 24-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 24 - trough FEV1 at baseline.
No measurements were reported for this outcome.
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major deterioration) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.
| score on a scale | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Mahler Transition Dyspnoea Index (TDI) Focal Score at the End of the 12-week Treatment Period | 1.000 ± 4.243 | 0.500 ± 3.536 | — | 3.333 ± 2.517 | -2.00 ± 2.828 |
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major deterioration) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.
No measurements were reported for this outcome.
The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations. The evaluation SGRQ was planned to be based upon pooled data from 48-week sister studies 1184.14 and 1184.15.
No measurements were reported for this outcome.
Time from start of treatment to first moderate to severe chronic obstructive pulmonary disease (COPD) exacerbation within 48 weeks is presented.
| Days | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Within 48 Weeks | — | 19.00 (19.00 to 19.00) | 41.00 (41.00 to 41.00) | — | 14.00 (14.00 to 14.00) |
Number of patients with moderate to severe chronic obstructive pulmonary disease (COPD) exacerbations within 48 weeks is presented.
| Count of participants | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| moderate | 0 | 1 | 1 | 0 | 1 |
| severe | 0 | 0 | 0 | 0 | 0 |
Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response after 4, 36 and 48 weeks treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 4, 36 or 48 - trough FEV1 at baseline.
| Litres (L) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 36 and 48 Weeks Treatment Period | 1.488 ± 0.654 | 1.259 ± 0.390 | 1.392 ± 0.605 | 1.516 ± 0.486 | 1.095 ± 0.447 |
Change from baseline in trough Forced Expiratory Volume in one second (FEV1) after 4, 36 and 48 weeks treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FEV1 response is defined as the change from baseline: Trough FEV1 response = Trough FEV1 - FEV1 (Baseline)
| Litres (L) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) After 4, 36 and 48 Weeks Treatment Period | 1.365 ± 0.629 | 1.155 ± 0.359 | 1.333 ± 0.573 | 1.408 ± 0.435 | 1.090 ± 0.455 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Peak FEV1 is defined as the highest FEV1 reading observed within 3 hours after inhalation of the morning dose of randomised treatment. Peak FEV1 response is defined as the change from baseline: Peak FEV1 response = Peak FEV1 - FEV1 (Baseline)
| Litres (L) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 0.293 ± 0.214 | 0.260 ± 0.178 | 0.237 ± 0.181 | 0.330 ± 0.195 | 0.108 ± 0.220 |
| week 12 | 0.228 ± 0.265 | 0.200 ± 0.042 | — | 0.103 ± 0.531 | 0.185 ± 0.177 |
Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC AUC0-8h is defined as the area under the FVC curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FVC was assigned to zero time. Trough FVC at baseline is defined as the pre-dose FVC measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FVC AUC0-8h at week 4, 12, 24, 36 or 48 - trough FVC at baseline.
| Millilitres (mL) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 0.451 ± 0.393 | 0.317 ± 0.334 | 0.243 ± 0.307 | 0.381 ± 0.393 | 0.010 ± 0.416 |
| week 12 | 0.316 ± 0.417 | 0.009 ± 0.009 | — | 0.208 ± 0.490 | 0.328 ± 0.410 |
Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC is defined as the pre-dose FVC measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FVC response is defined as the change from baseline: Trough FVC response = Trough FVC - FVC (Baseline)
| Millilitres (mL) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 0.201 ± 0.332 | 0.160 ± 0.287 | 0.175 ± 0.318 | 0.236 ± 0.426 | -0.037 ± 0.394 |
| week 12 | 0.058 ± 0.173 | 0.020 ± 0.085 | — | 0.253 ± 0.406 | -0.060 ± 0.028 |
Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Peak FVC is defined as the highest FVC reading observed within 3 hours after inhalation of the morning dose of randomised treatment. Peak FVC response is defined as the change from baseline: Peak FVC response = Peak FVC - FVC (Baseline)
| Millilitres (mL) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 0.592 ± 0.420 | 0.462 ± 0.313 | 0.401 ± 0.361 | 0.544 ± 0.410 | 0.178 ± 0.480 |
| week 12 | 0.385 ± 0.503 | 0.125 ± 0.021 | — | 0.398 ± 0.615 | 0.420 ± 0.438 |
Forced Expiratory Volume in one second (FEV1) at clinic visits at the individual times on week 4 is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer.
| Litres (L) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| 0 hours | 1.365 ± 0.629 | 1.155 ± 0.359 | 1.333 ± 0.573 | 1.408 ± 0.435 | 1.089 ± 0.447 |
| 30 minutes | 1.463 ± 0.654 | 1.228 ± 0.406 | 1.390 ± 0.599 | 1.546 ± 0.478 | 1.091 ± 0.437 |
| 1 hour | 1.487 ± 0.671 | 1.281 ± 0.423 | 1.414 ± 0.598 | 1.564 ± 0.508 | 1.113 ± 0.447 |
| 2 hours | 1.495 ± 0.641 | 1.266 ± 0.393 | 1.430 ± 0.615 | 1.561 ± 0.530 | 1.100 ± 0.456 |
| 3 hours | 1.505 ± 0.650 | 1.263 ± 0.406 | 1.409 ± 0.626 | 1.559 ± 0.516 | 1.125 ± 0.447 |
| 4 hours | 1.520 ± 0.670 | 1.276 ± 0.390 | 1.404 ± 0.594 | 1.525 ± 0.493 | 1.117 ± 0.450 |
| 6 hours | 1.484 ± 0.657 | 1.267 ± 0.392 | 1.377 ± 0.612 | 1.511 ± 0.485 | 1.091 ± 0.445 |
| 8 hours | 1.455 ± 0.647 | 1.226 ± 0.389 | 1.351 ± 0.621 | 1.428 ± 0.464 | 1.063 ± 0.433 |
Forced Expiratory Volume in one second (FEV1) at clinic visits at the individual times on week 12 is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer.
| Litres (L) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| 0 hours | 1.530 ± 0.598 | 0.990 ± 0.283 | — | 1.905 ± 0.520 | 0.640 ± 0.537 |
| 30 minutes | 1.575 ± 0.579 | 1.050 ± 0.311 | — | 1.960 ± 0.518 | 0.805 ± 0.587 |
| 1 hour | 1.643 ± 0.650 | 1.090 ± 0.297 | — | 1.993 ± 0.499 | 1.790 ± 0.566 |
| 2 hours | 1.675 ± 0.630 | 1.120 ± 0.368 | — | 1.988 ± 0.494 | 0.800 ± 0.566 |
| 3 hours | 1.650 ± 0.614 | 1.095 ± 0.431 | — | 2.005 ± 0.478 | 0.815 ± 0.502 |
| 4 hours | 1.703 ± 0.642 | 1.030 ± 0.354 | — | 1.963 ± 0.497 | 0.805 ± 0.516 |
| 6 hours | 1.658 ± 0.659 | 1.010 ± 0.255 | — | 1.908 ± 0.546 | 0.823 ± 0.562 |
| 8 hours | 1.673 ± 0.627 | 0.960 ± 0.339 | — | 1.885 ± 0.601 | 0.795 ± 0.544 |
Forced Vital Capacity (FVC) at clinic visits at the individual times on week 4 is presented. Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible.
| Millilitres (mL) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| 0 hours | 2.864 ± 1.094 | 2.680 ± 0.736 | 2.738 ± 0.887 | 3.018 ± 0.778 | 2.394 ± 0.710 |
| 30 minutes | 3.041 ± 1.100 | 2.761 ± 0.826 | 2.803 ± 0.901 | 3.200 ± 0.785 | 2.436 ± 0.832 |
| 1 hour | 3.123 ± 1.116 | 2.887 ± 0.845 | 2.843 ± 0.936 | 3.216 ± 0.798 | 2.464 ± 0.772 |
| 2 hours | 3.133 ± 1.106 | 2.870 ± 0.827 | 2.888 ± 0.929 | 3.234 ± 0.816 | 2.409 ± 0.842 |
| 3 hours | 3.140 ± 1.106 | 2.840 ± 0.805 | 2.848 ± 0.957 | 3.189 ± 0.771 | 2.437 ± 0.821 |
| 4 hours | 3.203 ± 1.183 | 2.836 ± 0.816 | 2.827 ± 0.917 | 3.156 ± 0.770 | 2.439 ± 0.799 |
| 6 hours | 3.109 ± 1.153 | 2.856 ± 0.810 | 2.767 ± 0.940 | 3.162 ± 0.840 | 2.423 ± 0.841 |
| 8 hours | 3.043 ± 1.141 | 2.806 ± 0.795 | 2.717 ± 0.989 | 3.061 ± 0.872 | 2.346 ± 0.826 |
Forced Vital Capacity (FVC) at clinic visits at the individual times on week 12 is presented. Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible.
| Millilitres (mL) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| 0 hours | 3.095 ± 1.001 | 1.920 ± 0.580 | — | 3.838 ± 1.047 | 1.455 ± 0.983 |
| 30 minutes | 3.300 ± 1.166 | 1.940 ± 0.396 | — | 3.983 ± 1.177 | 1.800 ± 0.636 |
| 1 hour | 3.313 ± 1.157 | 1.980 ± 0.467 | — | 3.795 ± 1.165 | 1.795 ± 0.573 |
| 2 hours | 3.378 ± 1.227 | 1.980 ± 0.410 | — | 3.863 ± 1.047 | 1.915 ± 0.544 |
| 3 hours | 3.333 ± 1.275 | 1.960 ± 0.566 | — | 3.865 ± 1.107 | 1.875 ± 0.431 |
| 4 hours | 3.425 ± 1.258 | 1.880 ± 0.495 | — | 3.753 ± 1.004 | 1.820 ± 0.566 |
| 6 hours | 3.383 ± 1.199 | 1.890 ± 0.481 | — | 3.730 ± 1.196 | 1.858 ± 0.527 |
| 8 hours | 3.308 ± 1.155 | 1.795 ± 0.516 | — | 3.728 ± 1.155 | 1.895 ± 0.488 |
Peak expiratory flow (PEF) rate at clinic visits at the individual times on week 4 is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.
| Litres/minute (L/min) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| 0 hours | 244.269 ± 107.320 | 219.357 ± 79.168 | 226.138 ± 92.890 | 270.100 ± 89.409 | 201.148 ± 70.055 |
| 30 minutes | 255.462 ± 109.075 | 231.607 ± 91.267 | 230.034 ± 97.724 | 286.833 ± 96.007 | 199.259 ± 75.244 |
| 1 hour | 261.462 ± 114,347 | 233.929 ± 87.890 | 234.517 ± 98.536 | 296.967 ± 104.571 | 197.222 ± 72.697 |
| 2 hours | 268.962 ± 118.729 | 242.386 ± 90.918 | 245.310 ± 99.846 | 304.733 ± 103.822 | 198.370 ± 74.688 |
| 3 hours | 262.923 ± 117.668 | 238.000 ± 90.849 | 240.793 ± 98.726 | 300.700 ± 109.300 | 203.889 ± 79.862 |
| 4 hours | 268.346 ± 120.842 | 245.560 ± 88.435 | 242.759 ± 96.366 | 302.511 ± 111.479 | 200.370 ± 77.459 |
| 6 hours | 261.538 ± 122.880 | 243.429 ± 91.812 | 233.310 ± 104.031 | 291.833 ± 103.339 | 195.148 ± 75.621 |
| 8 hours | 259.346 ± 119.517 | 236.464 ± 92.758 | 240.103 ± 100.926 | 279.800 ± 101.988 | 195.593 ± 77.674 |
Peak expiratory flow (PEF) rate at clinic visits at the individual times on week 12 is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.
| Litres/minute (L/min) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| 0 hours | 280.000 ± 142.164 | 189.000 ± 73.539 | — | 368.750 ± 87.717 | 122.500 ± 132.229 |
| 30 minutes | 294.250 ± 169.230 | 179.500 ± 60.104 | — | 375.750 ± 103.035 | 171.500 ± 88.388 |
| 1 hour | 300.500 ± 158.437 | 190.000 ± 65.054 | — | 383.250 ± 80.081 | 141.000 ± 148.492 |
| 2 hours | 313.250 ± 172.386 | 195.500 ± 74.246 | — | 391.500 ± 81.668 | 172.500 ± 159.099 |
| 3 hours | 304.500 ± 165.291 | 178.500 ± 86.974 | — | 385.500 ± 83.927 | 165.000 ± 104.652 |
| 4 hours | 302.250 ± 173.899 | 189.500 ± 105.359 | — | 377.000 ± 87.189 | 186.000 ± 87.681 |
| 6 hours | 310.250 ± 173.893 | 174.000 ± 67.882 | — | 365.000 ± 88.871 | 198.750 ± 106.420 |
| 8 hours | 296.750 ± 181.926 | 183.000 ± 108.894 | — | 372.750 ± 120.453 | 207.000 ± 118.794 |
Weekly mean morning pre-dose peak expiratory flows (PEFs) is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. The pulmonary function test was obtained by spirometry. The best of three efforts was defined as the highest PEF. Patients did not take their morning study medications prior to each morning PEF measurement.
| Litres / minute (L/min) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 1 | 225.9 ± 127.91 | 230.1 ± 101.15 | 218.3 ± 92.13 | 259.9 ± 112.47 | 190.9 ± 83.92 |
| week 2 | 231.3 ± 134.04 | 220.2 ± 101.3 | 223.6 ± 96.95 | 262.1 ± 108.16 | 192.1 ± 81.01 |
| week 3 | 236.9 ± 139.85 | 222.4 ± 98.34 | 225.3 ± 99.27 | 265.6 ± 112.97 | 190.4 ± 82.71 |
| week 4 | 233.1 ± 143.04 | 229.4 ± 96.99 | 226.3 ± 101.88 | 266.7 ± 113.45 | 196.3 ± 92.13 |
| week 5 | 232.1 ± 138.20 | 221.1 ± 105.67 | 221.4 ± 102.96 | 279.1 ± 104.92 | 187.5 ± 87.08 |
| week 6 | 229.9 ± 140.33 | 219.7 ± 101.17 | 219.3 ± 106.89 | 278.2 ± 109.25 | 194.9 ± 94.60 |
| week 7 | 246.6 ± 136.21 | 225.4 ± 101.29 | 230.3 ± 113.45 | 278.6 ± 109.83 | 193.1 ± 94.19 |
| week 8 | 260.1 ± 135.13 | 243.7 ± 111.59 | 236.2 ± 120.61 | 269.1 ± 106.93 | 190.1 ± 102.04 |
| week 9 | 245.3 ± 139.43 | 250.8 ± 117.74 | 236.0 ± 117.38 | 277.4 ± 107.30 | 203.3 ± 120.71 |
| week 10 | 252.2 ± 146.94 | 217.3 ± 74.54 | 229.6 ± 106.37 | 296.2 ± 106.31 | 153.8 ± 71.45 |
| week 11 | 266.7 ± 157.37 | 212.8 ± 71.11 | 219.2 ± 105.21 | 310.5 ± 118.90 | 163.3 ± 70.18 |
| week 12 | 251.7 ± 145.50 | 213.6 ± 84.51 | 207.3 ± 105.93 | 325.5 ± 105.79 | 166.1 ± 70.81 |
| week 13 | 311.2 ± 196.52 | 168.8 ± 109.64 | — | 376.3 ± 93.14 | — |
| week 14 | 327.3 | 241.7 | — | 328.3 ± 0.81 | — |
Weekly mean evening pre-dose peak expiratory flows (PEFs) is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. The pulmonary function test was obtained by spirometry. The best of three efforts was defined as the highest PEF. Patients did not take their evening study medications prior to each evening PEF measurement.
| Litres / minute (L/min) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 1 | 246.6 ± 129.31 | 249.0 ± 103.75 | 224.1 ± 92.95 | 271.3 ± 111.79 | 205.2 ± 81.10 |
| week 2 | 250.4 ± 136.64 | 243.3 ± 100.91 | 229.8 ± 93.81 | 275.3 ± 108.00 | 208.5 ± 74.46 |
| week 3 | 255.4 ± 140.86 | 243.3 ± 101.52 | 228.2 ± 99.94 | 277.1 ± 116.62 | 207.3 ± 79.52 |
| week 4 | 257.1 ± 145.90 | 249.2 ± 101.77 | 225.9 ± 102.01 | 276.7 ± 116.87 | 205.9 ± 89.26 |
| week 5 | 250.4 ± 144.68 | 238.1 ± 102.07 | 229.4 ± 103.43 | 286.2 ± 112.48 | 210.5 ± 89.21 |
| week 6 | 249.9 ± 143.58 | 237.4 ± 101.29 | 227.0 ± 102.44 | 279.1 ± 116.73 | 203.7 ± 89.21 |
| week 7 | 254.8 ± 142.14 | 241.0 ± 102.97 | 238.4 ± 107.19 | 283.3 ± 123.29 | 208.3 ± 94.49 |
| week 8 | 274.9 ± 148.12 | 258.7 ± 115.92 | 229.3 ± 112.63 | 283.8 ± 116.20 | 194.1 ± 100.58 |
| week 9 | 267.5 ± 150.16 | 239.8 ± 86.10 | 230.8 ± 111.89 | 293.4 ± 112.33 | 205.0 ± 111.36 |
| week 10 | 273.5 ± 155.67 | 243.3 ± 76.29 | 242.1 ± 105.29 | 311.8 ± 114.71 | 165.4 ± 62.62 |
| week 11 | 279.6 ± 168.14 | 227.4 ± 68.57 | 220.0 ± 101.51 | 311.7 ± 116.24 | 171.7 ± 70.29 |
| week 12 | 272.6 ± 158.77 | 221.8 ± 83.28 | 194.0 ± 101.34 | 333.0 ± 112.61 | 160.0 ± 86.92 |
| week 13 | 337.1 ± 214.03 | 201.8 ± 112.55 | — | 397.5 ± 114.15 | — |
| week 14 | 365.5 | 290.3 | — | 349.8 ± 15.56 | — |
Peak expiratory flow (PEF) are determined by spirometry at clinic visits (week 4, 12, 18, 24, 36 and 48) is presented. Spirometry will begin between 07:00 and 10:00 a.m. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.
| Litres/minute (L/min) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 268.962 ± 118.729 | 245.560 ± 88.435 | 245.310 ± 99.846 | 304.733 ± 103.822 | 203.889 ± 79.862 |
| week 12 | 313.250 ± 172.386 | 195.500 ± 74.246 | — | 391.500 ± 81.668 | 207.000 ± 118.794 |
Weekly mean morning pre-dose Forced expiratory volume in one second (FEV1) is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 measurements are performed individually at home and reported by the patient. It is measured by a spirometer. The best of three efforts was defined as the highest FEV1. Patients did not take their morning study medications prior to each morning FEV1 measurement.
| Litres (L) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 1 | 1.3 ± 0.71 | 1.1 ± 0.38 | 1.2 ± 0.52 | 1.4 ± 0.52 | 1.1 ± 0.41 |
| week 2 | 1.3 ± 0.75 | 1.0 ± 0.34 | 1.2 ± 0.49 | 1.4 ± 0.49 | 1.0 ± 0.38 |
| week 3 | 1.4 ± 0.74 | 1.1 ± 0.37 | 1.2 ± 0.47 | 1.4 ± 0.51 | 1.1 ± 0.39 |
| week 4 | 1.3 ± 0.73 | 1.1 ± 0.37 | 1.3 ± 0.52 | 1.4 ± 0.54 | 1.1 ± 0.45 |
| week 5 | 1.3 ± 0.77 | 1.0 ± 0.32 | 1.2 ± 0.51 | 1.4 ± 0.54 | 1.0 ± 0.38 |
| week 6 | 1.4 ± 0.77 | 1.0 ± 0.32 | 1.2 ± 0.51 | 1.4 ± 0.59 | 1.0 ± 0.38 |
| week 7 | 1.4 ± 0.76 | 1.0 ± 0.34 | 1.3 ± 0.53 | 1.4 ± 0.57 | 1.0 ± 0.39 |
| week 8 | 1.5 ± 0.77 | 1.1 ± 0.36 | 1.3 ± 0.55 | 1.4 ± 0.60 | 1.0 ± 0.37 |
| week 9 | 1.5 ± 0.70 | 1.1 ± 0.35 | 1.3 ± 0.52 | 1.5 ± 0.59 | 1.0 ± 0.46 |
| week 10 | 1.4 ± 0.65 | 1.1 ± 0.32 | 1.3 ± 0.47 | 1.5 ± 0.69 | 0.8 ± 0.24 |
| week 11 | 1.5 ± 0.69 | 1.0 ± 0.25 | 1.3 ± 0.49 | 1.5 ± 0.73 | 0.8 ± 0.21 |
| week 12 | 1.4 ± 0.51 | 1.0 ± 0.38 | 1.2 ± 0.45 | 1.6 ± 0.72 | 0.8 ± 0.23 |
| week 13 | 1.3 ± 0.68 | 0.8 ± 0.34 | — | 2.0 ± 1.07 | — |
| week 14 | 1.4 | 0.8 | — | 1.6 ± 0.05 | — |
Weekly mean evening pre-dose Forced expiratory volume in one second (FEV1) is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 measurements are performed individually at home and reported by the patient. It is measured by a spirometer. The best of three efforts was defined as the highest FEV1. Patients did not take their evening study medications prior to each evening FEV1 measurement.
| Litres (L) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 1 | 1.4 ± 0.73 | 1.2 ± 0.46 | 1.2 ± 0.48 | 1.4 ± 0.55 | 1.1 ± 0.40 |
| week 2 | 1.4 ± 0.75 | 1.2 ± 0.42 | 1.2 ± 0.47 | 1.4 ± 0.48 | 1.1 ± 0.40 |
| week 3 | 1.4 ± 0.77 | 1.1 ± 0.39 | 1.2 ± 0.49 | 1.4 ± 0.54 | 1.1 ± 0.42 |
| week 4 | 1.4 ± 0.76 | 1.2 ± 0.40 | 1.3 ± 0.48 | 1.5 ± 0.54 | 1.1 ± 0.44 |
| week 5 | 1.4 ± 0.78 | 1.1 ± 0.35 | 1.3 ± 0.51 | 1.4 ± 0.53 | 1.1 ± 0.39 |
| week 6 | 1.4 ± 0.79 | 1.1 ± 0.34 | 1.3 ± 0.49 | 1.4 ± 0.61 | 1.1 ± 0.40 |
| week 7 | 1.4 ± 0.73 | 1.1 ± 0.36 | 1.3 ± 0.50 | 1.4 ± 0.58 | 1.1 ± 0.39 |
| week 8 | 1.5 ± 0.77 | 1.2 ± 0.41 | 1.3 ± 0.51 | 1.5 ± 0.66 | 1.0 ± 0.39 |
| week 9 | 1.6 ± 0.78 | 1.1 ± 0.42 | 1.3 ± 0.47 | 1.5 ± 0.63 | 1.0 ± 0.47 |
| week 10 | 1.5 ± 0.66 | 1.2 ± 0.38 | 1.4 ± 0.44 | 1.5 ± 0.72 | 0.9 ± 0.25 |
| week 11 | 1.6 ± 0.69 | 1.1 ± 0.35 | 1.2 ± 0.39 | 1.6 ± 0.72 | 0.9 ± 0.29 |
| week 12 | 1.4 ± 0.55 | 1.1 ± 0.37 | 1.2 ± 0.42 | 1.6 ± 0.80 | 0.9 ± 0.35 |
| week 13 | 1.4 ± 0.66 | 0.9 ± 0.22 | — | 2.2 ± 1.09 | — |
| week 14 | 1.6 | 1.0 | — | 1.8 ± 0.07 | — |
Weekly mean number per day of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).
| count of puffs per day | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 1 | 1.8 ± 2.76 | 1.7 ± 2.63 | 2.6 ± 3.90 | 1.9 ± 2.67 | 4.7 ± 4.57 |
| week 2 | 1.3 ± 2.13 | 2.0 ± 2.86 | 2.3 ± 3.62 | 1.8 ± 2.81 | 5.3 ± 5.13 |
| week 3 | 1.4 ± 2.29 | 1.9 ± 2.97 | 1.9 ± 3.32 | 1.4 ± 2.34 | 5.1 ± 5.24 |
| week 4 | 1.1 ± 2.22 | 1.5 ± 2.89 | 2.5 ± 3.65 | 1.7 ± 2.48 | 5.0 ± 5.09 |
| week 5 | 1.1 ± 2.41 | 2.0 ± 2.94 | 2.7 ± 3.91 | 1.2 ± 1.60 | 4.2 ± 4.14 |
| week 6 | 1.2 ± 2.26 | 1.9 ± 2.71 | 2.4 ± 3.74 | 1.3 ± 1.80 | 4.7 ± 4.71 |
| week 7 | 1.1 ± 2.43 | 2.1 ± 3.11 | 2.1 ± 3.61 | 1.8 ± 2.44 | 5.4 ± 5.25 |
| week 8 | 1.0 ± 2.49 | 1.7 ± 2.38 | 2.4 ± 4.11 | 1.4 ± 2.49 | 5.7 ± 5.78 |
| week 9 | 1.1 ± 2.58 | 1.7 ± 2.57 | 1.9 ± 3.88 | 1.4 ± 2.09 | 5.4 ± 5.42 |
| week 10 | 0.3 ± 0.72 | 1.7 ± 2.31 | 1.6 ± 3.99 | 1.6 ± 1.85 | 3.7 ± 3.00 |
| week 11 | 0.7 ± 1.42 | 1.9 ± 2.51 | 2.7 ± 4.25 | 1.6 ± 1.86 | 2.7 ± 2.38 |
| week 12 | 1.3 ± 1.78 | 1.5 ± 1.90 | 1.7 ± 3.08 | 1.7 ± 2.64 | 2.3 ± 2.93 |
| week 13 | 1.0 ± 1.65 | 1.1 ± 0.20 | — | 1.3 ± 2.69 | — |
| week 14 | 0.0 | 1.3 | — | 0.6 ± 0.91 | — |
Weekly mean number at daytime of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).
| count of puffs | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 1 | 1.2 ± 1.75 | 1.3 ± 1.80 | 1.9 ± 3.00 | 1.3 ± 1.77 | 3.0 ± 3.11 |
| week 2 | 1.0 ± 1.60 | 1.4 ± 1.86 | 1.8 ± 2.97 | 1.1 ± 1.77 | 3.2 ± 3.21 |
| week 3 | 0.9 ± 1.73 | 1.3 ± 1.95 | 1.7 ± 3.04 | 0.9 ± 1.48 | 3.0 ± 3.31 |
| week 4 | 1.0 ± 1.83 | 1.0 ± 1.87 | 1.9 ± 3.18 | 1.0 ± 1.55 | 3.1 ± 3.48 |
| week 5 | 0.8 ± 1.80 | 1.4 ± 1.96 | 2.1 ± 3.19 | 0.7 ± 0.91 | 2.7 ± 2.75 |
| week 6 | 0.8 ± 1.70 | 1.2 ± 1.68 | 1.9 ± 3.30 | 1.0 ± 1.16 | 2.9 ± 3.09 |
| week 7 | 0.9 ± 1.86 | 1.3 ± 1.90 | 1.7 ± 3.18 | 1.1 ± 1.29 | 3.3 ± 3.54 |
| week 8 | 0.9 ± 2.00 | 1.2 ± 1.69 | 2.0 ± 3.66 | 0.8 ± 1.30 | 3.4 ± 3.67 |
| week 9 | 0.7 ± 1.95 | 1.3 ± 1.95 | 1.6 ± 3.50 | 0.9 ± 1.22 | 3.5 ± 3.60 |
| week 10 | 0.3 ± 0.76 | 1.2 ± 1.40 | 1.4 ± 3.98 | 1.1 ± 1.14 | 2.8 ± 2.35 |
| week 11 | 0.5 ± 0.88 | 1.3 ± 1.74 | 2.2 ± 4.21 | 1.0 ± 1.13 | 2.1 ± 2.67 |
| week 12 | 0.6 ± 0.95 | 1.0 ± 1.20 | 0.9 ± 1.45 | 1.0 ± 1.36 | 1.8 ± 2.95 |
| week 13 | 0.4 ± 0.66 | 1.0 ± 0.26 | — | 0.7 ± 1.44 | — |
| week 14 | 0.0 | 1.0 | — | 0.6 ± 0.91 | — |
Weekly mean number at nighttime of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).
| count of puffs | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 1 | 0.6 ± 1.09 | 0.4 ± 1.04 | 0.7 ± 1.24 | 0.6 ± 1.06 | 1.6 ± 1.69 |
| week 2 | 0.4 ± 0.76 | 0.7 ± 1.18 | 0.6 ± 1.22 | 0.7 ± 1.18 | 2.0 ± 2.18 |
| week 3 | 0.4 ± 0.71 | 0.7 ± 1.14 | 0.4 ± 0.77 | 0.5 ± 1.02 | 2.0 ± 2.26 |
| week 4 | 0.3 ± 0.60 | 0.5 ± 1.15 | 0.6 ± 1.05 | 0.7 ± 1.22 | 1.9 ± 1.99 |
| week 5 | 0.3 ± 0.62 | 0.6 ± 1.19 | 0.7 ± 1.17 | 0.4 ± 0.77 | 1.5 ± 1.83 |
| week 6 | 0.3 ± 0.61 | 0.6 ± 1.18 | 0.5 ± 0.89 | 0.6 ± 0.85 | 1.8 ± 1.97 |
| week 7 | 0.3 ± 0.63 | 0.7 ± 1.35 | 0.4 ± 0.83 | 0.8 ± 1.37 | 2.1 ± 2.07 |
| week 8 | 0.3 ± 0.67 | 0.4 ± 1.07 | 0.4 ± 0.85 | 0.6 ± 1.25 | 2.2 ± 2.57 |
| week 9 | 0.4 ± 0.80 | 0.4 ± 0.64 | 0.3 ± 0.88 | 0.5 ± 0.98 | 1.9 ± 2.46 |
| week 10 | 0.1 ± 0.30 | 0.5 ± 0.99 | 0.2 ± 0.37 | 0.6 ± 0.92 | 0.9 ± 1.14 |
| week 11 | 0.3 ± 0.58 | 0.6 ± 0.93 | 0.4 ± 0.72 | 0.6 ± 0.84 | 0.6 ± 0.63 |
| week 12 | 0.6 ± 1.01 | 0.4 ± 0.87 | 1.0 ± 2.00 | 0.7 ± 1.31 | 0.5 ± 0.55 |
| week 13 | 0.6 ± 0.99 | 0.2 ± 0.06 | — | 0.6 ± 1.25 | — |
| week 14 | 0.0 | 0.3 | — | 0.0 ± 0.00 | — |
Weekly mean number of chronic obstructive pulmonary disease (COPD)-related nighttime awakenings is presented.
| count of awakenings per nighttime | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 1 | 0.3 ± 0.54 | 0.1 ± 0.41 | 0.2 ± 0.50 | 0.2 ± 0.43 | 0.3 ± 0.49 |
| week 2 | 0.2 ± 0.30 | 0.2 ± 0.48 | 0.2 ± 0.40 | 0.1 ± 0.34 | 0.4 ± 0.49 |
| week 3 | 0.1 ± 0.18 | 0.2 ± 0.54 | 0.2 ± 0.40 | 0.1 ± 0.31 | 0.3 ± 0.49 |
| week 4 | 0.1 ± 0.32 | 0.2 ± 0.56 | 0.1 ± 0.26 | 0.1 ± 0.21 | 0.4 ± 0.58 |
| week 5 | 0.1 ± 0.26 | 0.2 ± 0.49 | 0.1 ± 0.12 | 0.1 ± 0.30 | 0.3 ± 0.52 |
| week 6 | 0.1 ± 0.38 | 0.2 ± 0.51 | 0.1 ± 0.21 | 0.3 ± 0.77 | 0.3 ± 0.52 |
| week 7 | 0.1 ± 0.22 | 0.1 ± 0.28 | 0.1 ± 0.19 | 0.3 ± 0.77 | 0.5 ± 0.61 |
| week 8 | 0.0 ± 0.09 | 0.1 ± 0.42 | 0.1 ± 0.15 | 0.3 ± 0.81 | 0.5 ± 0.62 |
| week 9 | 0.1 ± 0.25 | 0.1 ± 0.43 | 0.1 ± 0.27 | 0.3 ± 0.71 | 0.5 ± 0.71 |
| week 10 | 0.0 ± 0.05 | 0.1 ± 0.44 | 0.0 ± 0.14 | 0.2 ± 0.51 | 0.4 ± 0.56 |
| week 11 | 0.2 ± 0.28 | 0.1 ± 0.32 | 0.0 ± 0.00 | 0.2 ± 0.49 | 0.4 ± 0.67 |
| week 12 | 0.2 ± 0.40 | 0.1 ± 0.42 | 0.0 ± 0.00 | 0.3 ± 0.67 | 0.3 ± 0.41 |
| week 13 | 0.1 ± 0.25 | 0.0 ± 0.00 | — | 0.2 ± 0.38 | — |
| week 14 | 0.0 | 0.0 | — | 0.0 ± 0.00 | — |
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major detonation) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.
| score on a scale | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Mahler Transition Dyspnoea Index (TDI) Focal Score Collected After 4, 36 and 48 Weeks Treatment Period | 0.346 ± 1.672 | 0.857 ± 2.460 | 0.966 ± 1.973 | 1.167 ± 2.321 | -1.407 ± 2.791 |
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - functional impairment is based on the criteria of change in functional impairment (any activities started or stopped?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).
| score on a scale | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 0.038 ± 0.662 | 0.250 ± 0.701 | 0.310 ± 0.712 | 0.400 ± 0.814 | -0.481 ± 1.014 |
| week 12 | 0.500 ± 1.000 | 0.000 ± 1.414 | — | 1.333 ± 0.577 | -0.500 ± 0.707 |
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - magnitude of task is based on the criteria of change in magnitude of task (What activities cause breathlessness now?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).
| score on a scale | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 0.269 ± 0.667 | 0.393 ± 0.875 | 0.345 ± 0.670 | 0.433 ± 0.858 | -0.296 ± 0.993 |
| week 12 | 0.250 ± 0.258 | 0.500 ± 0.707 | — | 1.000 ± 1.000 | -0.500 ± 0.707 |
The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - magnitude of effort is based on the criteria of change in magnitude of effort (Need to pause while performing activities?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).
| score on a scale | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 0.038 ± 0.662 | 0.214 ± 0.995 | 0.310 ± 0.761 | 0.333 ± 0.884 | -0.630 ± 0.967 |
| week 12 | 0.250 ± 2.062 | 0.000 ± 1.414 | — | 1.000 ± 1.000 | -1.000 ± 1.414 |
The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.
| Score on a scale | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 37.611 ± 19.088 | 41.649 ± 18.439 | 38.070 ± 16.663 | 41.107 ± 19.453 | 52.655 ± 22.068 |
| week 12 | 45.631 ± 34.961 | 40.625 ± 25.601 | — | 24.167 ± 19.214 | 55.332 ± 30.430 |
The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The impact domain score is a part of the SGRQ that measures the impact of disease on daily life. Its scores range from 0 to 100, with higher scores indicating more limitations.
| Score on a scale | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 26.733 ± 18.881 | 29.872 ± 17.858 | 26.145 ± 16.484 | 30.515 ± 20.269 | 41.308 ± 23.463 |
| week 12 | 36.576 ± 33.489 | 26.686 ± 22.801 | — | 13.830 ± 14.373 | 42.214 ± 25.362 |
The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The activity domain score is a part of the SGRQ that measures the activity of the patient. Its scores range from 0 to 100, with higher scores indicating more limitations.
| Score on a scale | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 53.592 ± 22.379 | 61.836 ± 20.579 | 58.923 ± 23.070 | 60.663 ± 22.449 | 68.334 ± 23.000 |
| week 12 | 53.254 ± 38.369 | 60.768 ± 17.352 | — | 41.428 ± 18.063 | 73.844 ± 36.990 |
The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The symptoms domain score is a part of the SGRQ that measures the symptoms of the patient. Its scores range from 0 to 100, with higher scores indicating more limitations.
| Score on a scale | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| week 4 | 43.178 ± 25.487 | 42.955 ± 24.837 | 38.346 ± 21.299 | 39.070 ± 26.939 | 60.312 ± 24.383 |
| week 12 | 60.664 ± 34.202 | 48.423 ± 49.610 | — | 25.706 ± 38.951 | 63.479 ± 34.656 |
Number of patients with adverse events within the 48-week treatment period is presented. A patient may be counted in more than one seriousness criterion.
| Count of participants | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| any adverse event (AE) | 8 | 10 | 10 | 5 | 9 |
| severe AE | 1 | 0 | 3 | 1 | 0 |
| investigator-defined drug-related AE | 1 | 5 | 1 | 0 | 2 |
| other significant AE (according to ICH-E3) | 1 | 1 | 0 | 0 | 2 |
| AE leading to discontinuation of trial drug | 0 | 0 | 2 | 1 | 2 |
| significant AE (pre-specified events) | 0 | 0 | 0 | 0 | 0 |
| serious AE (fatal) | 0 | 0 | 1 | 1 | 0 |
| serious AE (life-threatening) | 0 | 0 | 0 | 0 | 0 |
| serious AE (disability) | 0 | 0 | 0 | 0 | 0 |
| serious AE (required hospitalisation) | 0 | 0 | 4 | 0 | 1 |
| serious AE (prolonged hospitalisation) | 0 | 0 | 0 | 0 | 0 |
| serious AE (congenital anomaly) | 0 | 0 | 0 | 0 | 0 |
| serious AE (other) | 0 | 0 | 0 | 0 | 0 |
Number of patients with marked changes in vital signs (decrease) by clinic visit is presented. Vital signs: pulse rate and blood pressure (BP) (after five minutes rest in seated position) recorded pre-dose on each pulmonary function test-day and in conjunction with spirometry for the first 3 hours post-dosing. Systolic BP Decrease: Below 100 mmHg if not at that level at baseline and a decrease of greater than 10 mmHg below baseline. Diastolic BP Decrease: Below 60 mmHg if not at that level at baseline and a decrease of greater than 10 mmHg below baseline. Pulse rate Decrease: Below 60 bpm if not at that level at baseline and a decrease of greater than 10 bpm below baseline.
| Count of participants | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| systolic BP (week 4) | 1 | 2 | 0 | 1 | 1 |
| systolic BP (week12) | 1 | 0 | 0 | 0 | 1 |
| diastolic BP (week 4) | 2 | 2 | 1 | 1 | 1 |
| diastolic BP (week 12) | 1 | 0 | 0 | 0 | 0 |
| pulse rate (week 4) | 0 | 1 | 1 | 0 | 2 |
| pulse rate (week 12) | 0 | 0 | 0 | 0 | 0 |
Number of patients with marked changes in vital signs (increase) by clinic visit is presented. Vital signs: pulse rate and blood pressure 8BP) (after five minutes rest in seated position) recorded pre-dose on each pulmonary function test-day and in conjunction with spirometry for the first 3 hours post-dosing. Systolic BP Increase : An increase of 25 mmHg or more above baseline. Diastolic BP Increase: Above 90 mmHg at baseline and an increase of greater than 10 mmHg above baseline. Pulse rate Increase : Greater than 100 bpm if not at that level at baseline and an increase greater than 10 above baseline.
| Count of participants | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| systolic BP (week 4) | 3 | 1 | 3 | 1 | 3 |
| systolic BP (week 12) | 0 | 0 | 0 | 0 | 0 |
| diastolic BP (week 4) | 1 | 3 | 4 | 2 | 2 |
| diastolic BP (week 12) | 0 | 0 | 0 | 1 | 0 |
| pulse rate (week 4) | 0 | 0 | 0 | 0 | 1 |
| pulse rate (week 12) | 0 | 0 | 0 | 0 | 0 |
Number of patients with abnormal haematology at the end of the 12-week treatment period is presented.
| Participants | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Increased white blood cell count | 1 | 0 | 0 | 0 | 0 |
| Decreased white blood cell count | 0 | 0 | 0 | 0 | 0 |
| Basophils increase | 0 | 0 | 0 | 0 | 0 |
| Basophils decrease | 0 | 0 | 0 | 0 | 0 |
| Eosinophils increase | 0 | 0 | 0 | 1 | 0 |
| Eosinophils decrease | 0 | 0 | 0 | 0 | 0 |
| Absolute eosinophils increase | 0 | 0 | 0 | 0 | 0 |
| Absolute eosinophils decrease | 0 | 0 | 0 | 0 | 0 |
| Haematocrit increase | 0 | 0 | 0 | 0 | 1 |
| Haematocrit decrease | 0 | 0 | 0 | 0 | 0 |
| Haemoglobin increase | 0 | 0 | 0 | 0 | 0 |
| Haemoglobin decrease | 0 | 0 | 0 | 0 | 0 |
| Absolute lymphocyte increase | 0 | 0 | 0 | 0 | 0 |
| Absolute lymphocyte decrease | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes increase | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes decrease | 1 | 0 | 0 | 0 | 0 |
| Absolute monocytes increase | 0 | 0 | 0 | 0 | 0 |
| Absolute monocytes decrease | 0 | 0 | 0 | 0 | 0 |
| Monocytes increase | 0 | 0 | 0 | 0 | 0 |
| Monocytes decrease | 1 | 0 | 0 | 0 | 0 |
| Absolute neutrophils increase | 1 | 0 | 0 | 1 | 1 |
| Absolute neutrophils decrease | 0 | 0 | 0 | 0 | 0 |
| Neutrophils increase | 1 | 0 | 0 | 1 | 1 |
| Neutrophils decrease | 0 | 0 | 0 | 0 | 0 |
| Platelets increase | 0 | 1 | 0 | 0 | 0 |
| Platelets decrease | 0 | 0 | 0 | 0 | 0 |
| Red blood cell morphology (qualitative) increase | 0 | 0 | 0 | 0 | 0 |
| Red blood cell morphology (qualitative) decrease | 0 | 0 | 0 | 0 | 0 |
| Red blood cell count increase | 0 | 0 | 0 | 0 | 0 |
| Red blood cell count decrease | 0 | 0 | 0 | 0 | 0 |
| Total eosinophil count increase | 0 | 0 | 0 | 0 | 0 |
| Total eosinophil count decrease | 0 | 0 | 0 | 0 | 0 |
| White blood cell morphology (qualitative) increase | 0 | 0 | 0 | 0 | 0 |
| White blood cell morphology (qualitative) decrease | 0 | 0 | 0 | 0 | 0 |
Number of patients with abnormal blood chemistry at the end of the 12-week treatment period is presented.
| Participants | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Alanine aminotransferase increase | 0 | 0 | 0 | 0 | 1 |
| Alanine amoínotransferase decrease | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase increase | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase decrease | 0 | 0 | 0 | 0 | 0 |
| Albumin increase | 0 | 0 | 0 | 0 | 0 |
| Albumin decrease | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increase | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase decrease | 0 | 0 | 0 | 0 | 0 |
| Total bilirubin increase | 0 | 0 | 0 | 0 | 0 |
| Total bilirubin decrease | 0 | 0 | 0 | 0 | 0 |
| Blood urea nitrogen increase | 0 | 0 | 0 | 0 | 0 |
| Blood urea nitrogen decrease | 0 | 0 | 0 | 0 | 0 |
| Calcium increase | 0 | 0 | 0 | 0 | 0 |
| Calcium decrease | 0 | 0 | 0 | 0 | 0 |
| Creatinine increase | 0 | 0 | 0 | 0 | 0 |
| Creatinine decrease | 0 | 0 | 0 | 0 | 0 |
| Gamma glutamyltransferase increase | 1 | 0 | 0 | 1 | 0 |
| Gamma glutamyltransferase decrease | 0 | 0 | 0 | 0 | 0 |
| Glucose increase | 0 | 0 | 0 | 0 | 0 |
| Glucose decrease | 0 | 0 | 0 | 0 | 0 |
| Lactate dehydrogenase increase | 0 | 0 | 0 | 0 | 0 |
| Lactate dehydrogenase decrease | 0 | 0 | 0 | 0 | 0 |
| Phosphate increase | 0 | 0 | 0 | 0 | 0 |
| Phosphate decrease | 0 | 0 | 0 | 0 | 0 |
| Potassium increase | 0 | 0 | 0 | 0 | 0 |
| Potassium decrease | 0 | 0 | 0 | 0 | 0 |
| Total protein increase | 0 | 0 | 0 | 0 | 0 |
| Total protein decrease | 0 | 0 | 0 | 0 | 0 |
| Sodium increase | 0 | 0 | 0 | 0 | 0 |
| Sodium decrease | 0 | 1 | 0 | 0 | 0 |
| Uric acid increase | 1 | 0 | 0 | 1 | 0 |
| Uric acid decrease | 0 | 0 | 0 | 0 | 0 |
Number of patients with abnormal urinalysis at the end of the 12-week treatment period is presented.
| Participants | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Urine blood (qualitative) increase | 0 | 0 | 0 | 0 | 0 |
| Urine blood (qualitative) decrease | 0 | 0 | 0 | 0 | 0 |
| Urine glucose (qualitative) increase | 0 | 0 | 0 | 0 | 0 |
| Urine glucose (qualitative) decrease | 0 | 0 | 0 | 0 | 0 |
| Urine pH increase | 0 | 0 | 0 | 0 | 0 |
| Urine pH decrease | 0 | 0 | 0 | 0 | 0 |
| Urine protein (qualitative) increase | 0 | 0 | 0 | 1 | 0 |
| Urine protein (qualitative) decrease | 0 | 0 | 0 | 0 | 0 |
| Urine specific gravity increase | 0 | 0 | 0 | 0 | 0 |
| Urine specific gravity decrease | 0 | 0 | 0 | 0 | 0 |
Vital status of randomised patients is presented.
No measurements were reported for this outcome.
Number of days in hospital within the 48-week treatment period is presented.
| days | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Number of Days in Hospital Within the 48-week Treatment Period | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.1 ± 0.9 | 0.0 ± 0.0 | 0.0 ± 0.0 |
Number of unscheduled health care provider visits within the 48-week treatment period is presented.
| count of visits | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Number of Unscheduled Health Care Provider Visits Within the 48-week Treatment Period | 0.02 ± 0.16 | 0.31 ± 0.87 | 0.04 ± 0.20 | 0.16 ± 0.43 | 0.16 ± 0.53 |
Number of emergency room visits within the 48-week treatment period is presented.
| count of visits | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Number of Emergency Room Visits Within the 48-week Treatment Period | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
Number of days in intensive care unit within the 48-week treatment period is presented.
| days | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Number of Days in Intensive Care Unit Within the 48-week Treatment Period | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
Number of patients receiving concomitant medication is presented. Concomitant medication was observed for rerandomized placebo patients during placebo treatment and on-treatment periods.
| Count of participants | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Number of Patients Receiving Concomitant Medication | 38 | 35 | 44 | 43 | 41 |
Collected over From first dose of study drug until end of week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FDC Tiotropium / Salmeterol (T+S_PE) | 0/43 (0%) | 0/43 (0%) | 1/43 (2.3%) |
| Tiotropium (Tio18GEL) | 0/42 (0%) | 1/42 (2.4%) | 1/42 (2.4%) |
| Salmeterol (Salm25PE) | 1/49 (2%) | 5/49 (10.2%) | 1/49 (2%) |
| FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | 1/44 (2.3%) | 1/44 (2.3%) | 0/44 (0%) |
| Placebo | 0/44 (0%) | 3/44 (6.8%) | 3/44 (6.8%) |
| Event | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/43 | 1/42 | 0/49 | 0/44 | 0/44 |
| PalpitationsCardiac disorders | 0/43 | 0/42 | 0/49 | 0/44 | 1/44 |
| Ventricular extrasystolesCardiac disorders | 0/43 | 0/42 | 0/49 | 0/44 | 1/44 |
| Angle closure glaucomaEye disorders | 0/43 | 0/42 | 0/49 | 0/44 | 1/44 |
| SyncopeNervous system disorders | 0/43 | 0/42 | 0/49 | 0/44 | 1/44 |
| ArteriosclerosisVascular disorders | 0/43 | 0/42 | 0/49 | 1/44 | 0/44 |
| Atrial flutterCardiac disorders | 0/43 | 0/42 | 1/49 | 0/44 | 0/44 |
| Myocardial infarctionCardiac disorders | 0/43 | 0/42 | 1/49 | 0/44 | 0/44 |
| Tendon disorderMusculoskeletal and connective tissue disorders | 0/43 | 0/42 | 1/49 | 0/44 | 0/44 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/43 | 0/42 | 1/49 | 0/44 | 0/44 |
| Event | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo |
|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/43 | 1/42 | 1/49 | 0/44 | 3/44 |
The treated set (TS): The treated set consists of all randomised patients who took at least one dose of study medication.
| Age, Continuous(Years) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 63.7 ± 9.0 | 66.3 ± 9.0 | 65.5 ± 9.3 | 62.8 ± 9.7 | 64.0 ± 8.4 | 64.5 ± 9.1 |
| Sex: Female, Male(Participants) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 16 | 16 | 18 | 13 | 16 | 79 |
| Male | 25 | 26 | 31 | 31 | 28 | 141 |
| Ethnicity (NIH/OMB)(Participants) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 | 0 | 2 |
| Not Hispanic or Latino | 41 | 42 | 48 | 43 | 44 | 218 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | FDC Tiotropium / Salmeterol (T+S_PE) | Tiotropium (Tio18GEL) | Salmeterol (Salm25PE) | FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE) | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 1 | 0 | 0 | 4 |
| White | 38 | 41 | 48 | 44 | 44 | 215 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Data sharing details ↗ · www.mystudywindow.com
Ran from Apr 2008 to primary completion in Nov 2008, 7 months.
Results were first posted in Oct 2026, 17 years 11 months after primary completion. A results delay was requested in Apr 2014.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →